Pierre Fabre has acquired the OTC business of UCB in France, Benelux, Switzerland and Greece. The acquisition includes certain mature products such as Carbolevure, Revitalose, Balsoclase, Toclase, which represent approximately $23 million in sales. UCB will continue to manufacture and supply some of the transferred products during a transitional period. The two companies have also have entered into a distribution agreement under which Pierre Fabre will market UCB’s leading anti-histam...